Takeda Forecasts Tripling In Reported Op Profit Despite Virus Uncertainties
Lower Shire-Related Costs
Executive Summary
While it has seen no coronavirus-related business impact so far and uncertainties remain, Takeda expects lower costs related to the Shire acquisition to propel its profits this fiscal year.
You may also be interested in...
EU Approves Takeda’s Injectable Entyvio for IBD
Takeda has won EU approval for an injectable version of Entyvio to treat ulcerative colitis or Crohn’s disease, in contrast to the FDA’s rejection in December.
Takeda Sheds More Non-Core Assets, Employees In $670m Orifarm Deal
Danish firm picks up portfolio and manufacturing sites, along with around 600 employees.
Takeda Kicks Off Effort On Globulin, Other COVID-19 Therapies
Japan's largest pharma firm has joined the global fray to develop potential therapies for the spreading coronavirus outbreak, focusing initially on its plasma products expertise. But this approach has had some challenges in China.